Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celldex Therapeutics, Inc.    

CELLDEX THERAPEUTICS, INC.

My previous session
Most popular
  Report  
End-of-day quote. End-of-day quote Nasdaq - 02/13
5.53 USD   +10.82%
02/11CELLDEX THERAPEUTICS : Announces Reverse Stock Split
AQ
02/11CELLDEX THERAPEUTICS, INC. : REVERSE SPLIT: 1 of 15
FA
02/11CELLDEX THERAPEUTICS, INC. : REVERSE SPLIT: 1 of 15
FA
 SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Financials (USD)
Sales 2018 9,20 M
EBIT 2018 -173 M
Net income 2018 -156 M
Debt 2018 -
Yield 2018 -
Sales 2019 5,10 M
EBIT 2019 -72,0 M
Net income 2019 -71,2 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 7,32x
Capi. / Sales2019 13,2x
Capitalization 67,4 M
More Financials
Company
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic... 
More about the company
Latest news on CELLDEX THERAPEUTICS, INC.
02/11CELLDEX THERAPEUTICS : Announces Reverse Stock Split
AQ
02/11CELLDEX THERAPEUTICS, INC. : REVERSE SPLIT: 1 of 15
FA
02/11CELLDEX THERAPEUTICS, INC. : REVERSE SPLIT: 1 of 15
FA
02/09CELLDEX THERAPEUTICS : Announces Reverse Stock Split
AQ
02/08CELLDEX THERAPEUTICS, INC. : Material Modification to Rights of Security Holders..
AQ
02/08Celldex Therapeutics Announces Reverse Stock Split
GL
2018CELLDEX THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K..
AQ
2018CELLDEX THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continu..
AQ
2018CELLDEX THERAPEUTICS : Presents Promising Interim Data from Phase 1 Study of Dif..
AQ
2018Celldex Presents Emerging MerTK Antibody Program at the Society for Immunothe..
GL
More news
Analyst Recommendations on CELLDEX THERAPEUTICS, INC.
More recommendations
Sector news : Biotechnology & Medical Research - NEC
02/15Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
RE
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/06Eli Lilly Cuts Earnings Forecast on Pending Loxo Acquisition
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart CELLDEX THERAPEUTICS, INC.
Duration : Period :
Celldex Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLDEX THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 32,3 $
Spread / Average Target 450%
EPS Revisions
Managers
NameTitle
Anthony S. Marucci President, Chief Executive Officer & Director
Larry Ellberger Chairman
Sam Martin Chief Financial Officer, Secretary & Senior VP
Tibor Keler Chief Scientific Officer & Executive VP
Karen Lipton Shoos Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLDEX THERAPEUTICS, INC.2,694.34%67
IQVIA HOLDINGS INC11.13%28 377
CELLTRION, INC.--.--%23 803
LONZA GROUP14.80%21 653
INCYTE CORPORATION31.18%17 908
SEATTLE GENETICS, INC.17.42%11 477